Next, we investigated whether the role of UBE2T in sorafenib resistance is clinically relevant by analyzing 30 HCC patients who received prior sorafenib treatment in TCGA-LIHC dataset. The gene discussed is UBE2T; the disease is hepatocellular carcinoma.